Human pluripotent stem cell engineering with CRISPR-Cas9 for Parkinson's disease

Area of Science:

• Neuroscience
• Stem Cell Biology
• Genetic Engineering

Background:

• Parkinson's disease (PD) is characterized by dopamine neuron loss and alpha-synuclein pathology.
• Current therapies for PD lack disease-modifying capabilities.
• Human pluripotent stem cells (hPS cells) offer potential for generating dopamine (DA) neurons for modeling and therapy.

Purpose of the Study:

• To develop precise human models for Parkinson's disease using hPS cells and CRISPR technology.
• To advance hPS cell-based cell therapies for PD by improving graft survival and function.
• To identify regulators of cell death and enhance DA neuron purification and control in vivo.

Main Methods:

• Utilizing hPS cells for large-scale generation of DA neurons.
• Employing CRISPR technology for causal genetic interrogation and reporter gene insertion.
• Conducting in vivo cell survival screens and reporter-guided enrichment of DA neurons.
• Implementing chemogenetic control for grafted DA cell function.

Main Results:

• CRISPR enabled precise genetic modeling of PD, including mitochondrial, lysosomal, and synaptic failures.
• hPS cell-based DA grafts showed potential for motor function restoration but faced significant in vivo cell death (>90%).
• CRISPR facilitated identification of cell death regulators and improved DA neuron enrichment and in vivo control.

Conclusions:

• hPS cells combined with CRISPR technology provide powerful tools for creating precise human PD models.
• These advancements are crucial for developing effective hPS cell-based regenerative therapies for Parkinson's disease.
• A roadmap is proposed to accelerate the clinical translation of these innovative approaches.